Abstract:Background Lowering intraocular pressure (IOP) is currently the only therapeutic approach in primary open-angle glaucoma. and the fixed-combination medications are needed to achieve sufficiently low target IOP. A multicenter prospective study in the Chinese population was needed to confirm the safety and efficacy of Bimatoprost/Timolol Fixed Combination Eye Drop in China. In this study, we evaluated the safety and efficacy of Bimatoprost/Timolol Fixed Combination with concurrent administration of its components in Chinese patients with open-angle glaucoma or ocular hypertension. Methods In this multicenter, randomized, double-masked, parallel controlled study, patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy with either topical β-blockers or prostaglandin analogues were randomized to one of two active treatment groups in a 1:1 ratio at 11 Chinese ophthalmic departments. Bimatoprost/timolol fixed combination treatment was a fixed combination of 0.03% bimatoprost and 0.5% timolol (followed by vehicle for masking) once daily at 19:00 P.M. and concurrent treatment was 0.03% bimatoprost followed by 0.5% timolol once daily at 19:00 P.M. The primary efficacy variable was change from baseline in mean diurnal intraocular pressure (IOP) at week 4 visit in the intent-to-treat (ITT) population. Primary analysis evaluated the non-inferiority of bimatoprost/timolol fixed combination to concurrent with respect to the primary variable using a confidence interval (CI) approach. Bimatoprost/timolol fixed combination was to be considered non-inferior to concurrent if the upper limit of the 95% CI for the between-treatment (bimatoprost/timolol fixed combination minus concurrent) difference was ≤1.5 mmHg. Adverse events were collected and slit-lamp examinations were performed to assess safety. Between-group comparisons of the incidence of adverse events were performed using the Pearson chi-square test or Fisher's exact test. Results Of the enrolled 235 patients, 121 patients were randomized to receive bimatoprost/timolol fixed combination and, 114 patients were randomized to receive concurrent treatment. At baseline the mean value of mean diurnal IOP was (25.20±3.06) mmHg in the bimatoprost/timolol fixed combination group and (24.87±3.88) mmHg in the concurrent group. The difference between the treatment groups was not statistically significant. The mean change from baseline in mean diurnal IOP (±standard deviation) in the bimatoprost/timolol fixed combination group was (−9.38±4.66) mmHg and it was (−8.93±4.25) mmHg in the concurrent group (P <0.01). The difference between the two treatment groups (bimatoprost/timolol fixed combination minus concurrent) in the change from baseline of mean diurnal IOP was -0.556 mmHg (95% CI: −1.68, 0.57, P=0.330). The upper limit of the 95% CI was less than 1.5 mmHg, the predefined margin of non-inferiority. Adverse events occurred in 26.4% (32/121) of the bimatoprost/timolol fixed combination patients and 30.7% (35/114) of the concurrent patients. The most frequent adverse event was conjunctival hyperemia, which was reported as treatment related in 16.5% (20/121) in the bimatoprost/timolol fixed combination group and 18.4% (21/114) in the concurrent group (P >0.05). Conclusions Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components. Safety profiles were similar between the treatment groups.

Clinic Application of Timolol Ophthalmic Gel

Clinical studies of D-timolol vs L-timolol

An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®

Timolol,brinzolamide and Travoprost in Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension

Intraocular Pressure-Lowering Effect of Tetrandrine and Timolol on Rats with Ocular Hypertension

Safety and Efficacy of Bimatoprost/timolol Fixed Combination in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension.

Treatment Effects of 0.5% Timolol on Refractive Regression in Eyes after Laser in Situ Keratomileusis

Efficacy and Safety of Travoprost Versus Timolol to Treat Early-Onset Ocular Hypertension Secondary to Vitrectomy: A Randomized Trial

Timolol 0.5% ophthalmic solution influences cardiac function in healthy cats

Pharmacokinetics Of Timolol In Aqueous Humor Sampled By Microdialysis After Topical Administration Of Thermosetting Gels

Comparison of Latanoprost and Brimonidine in the Treatment of Open Angle Glaucoma

A Meta-Analysis of Therapy Comparison Between Bimatoprost and Timolol in Ocular Hypertention Eye

The Effect of Timolol 0.5% on the Correction of Myopic Regression after LASIK

[Randomized Parallel Group Study of 0.0015% Tafluprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension (comparison with 0.005% Latanoprost Ophthalmic Solution)].

Efficacy and Safety of Introduction Timolol Maleate by Manometer Microneedles among Infantile Hemangioma: A Retrospective Study in China

Intraocular Pressure-Lowering Efficacy and Safety of Bimatoprost 0.03% Therapy for Primary Open-Angle Glaucoma and Ocular Hypertension Patients in China.

Effectiveness and tolerability of the fixed combination of preservative-free drugs timolol and travoprost in glaucoma patients after cataract surgery

Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.

Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial

Short-term effects of ophthalmic topical 0.01% atropine on the ocular surface, pupil size, and subsequent subjective quality of vision in young myopic Chinese adults

Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension.